Page 1088 - Hall et al (2015) Principles of Critical Care-McGraw-Hill
P. 1088

References     3


                      74. Haddow AD,  Odoi  A.  The  incidence risk,  clustering,  and     97. Centers  for  Disease Control  and  Prevention  (CDC).  Update:
                        clinical presentation of La Crosse virus infections in the eastern   measles–United States, January-July 2008. MMWR Morb Mortal
                        United States, 2003-2007. PLoS One. 2009;4(7):e6145.    Wkly Rep. 2008;57(33):893-896.
                      75. McJunkin JE, et al. La Crosse encephalitis in children. N Engl J     98. Perry  RT,  Halsey NA. The  clinical  significance  of measles:  a
                        Med. 2001;344(11):801-807.                              review. J Infect Dis. 2004;189(suppl 1):S4-S16.
                      76. Haddow AD. The use of oral ribavirin in the management of La     99. Johnson RT, et al. Measles encephalomyelitis—clinical and
                        Crosse viral infections. Med Hypotheses. 2009;72(2):190-192.  immunologic studies. N Engl J Med. 1984;310(3):137-141.
                      77. Zacks MA, Paessler S. Encephalitic alphaviruses. Vet Microbiol.     100. Sabella C. Measles: not just a childhood rash. Cleve Clin J Med.
                        2010;140(3-4):281-286.                                  2010;77(3):207-213.
                      78. Figueiredo CA, et al. Rubella encephalitis in a young adult male:     101. Gutierrez J, Issacson RS, Koppel BS. Subacute scleros-
                        isolation and genotype analysis. Infection. 2011;39(1):73-75.  ing panencephalitis: an update.  Dev Med Child Neurol.
                      79. Squadrini F, et al. Rubella virus isolation from cerebro-  2010;52(10):901-907.
                        spinal fluid in postnatal rubella encephalitis.  Br  Med  J.     102. Praveen-kumar S, et al. Electroencephalographic and imaging
                        1977;2(6098):1329-1330.                                 profile in a subacute sclerosing panencephalitis (SSPE) cohort:
                      80. Lau KK, et al. Acute encephalitis complicating rubella.  Hong   a correlative study. Clin Neurophysiol. 2007;118(9):1947-1954.
                        Kong Med J. 1998;4(3):325-328.                       103. Oguz KK, Celebi A, Anlar B. MR imaging, diffusion-weighted
                      81. Hankins DG, Rosekrans JA. Overview, prevention, and treat-  imaging and MR spectroscopy findings in acute rapidly
                        ment of rabies. Mayo Clin Proc. 2004;79(5):671-676.     progressive subacute sclerosing panencephalitis.  Brain Dev.
                      82. Leung AK, Davies HD, Hon K.L. Rabies: epidemiology, patho-  2007;29(5):306-311.
                        genesis, and prophylaxis. Adv Ther. 2007;24(6):1340-1347.    104. Gascon GG. Randomized treatment study of inosiplex versus
                      83. Dietzschold B, Schnell M, Koprowski H. Pathogenesis of rabies.   combined inosiplex and intraventricular interferon-alpha in
                        Curr Top Microbiol Immunol. 2005;292:45-56.             subacute sclerosing panencephalitis (SSPE): international mul-
                                                                                ticenter study. J Child Neurol. 2003;18(12):819-827.
                      84. Dimaano EM, et al. Clinical and epidemiological features of
                        human rabies cases in the Philippines: a review from 1987 to     105. Hara S, et al. Combination therapy with intraventricular
                        2006. Int J Infect Dis. 2011;15(7):e495-e499.             interferon-alpha and ribavirin for subacute sclerosing panen-
                      85. Jackson AC. Rabies in the critical care unit: diagnostic and   cephalitis and monitoring measles virus RNA by quantitative
                        therapeutic approaches. Can J Neurol Sci. 2011;38(5):689-695.  PCR assay. Brain Dev. 2003;25(5):367-369.
                      86. Manning SE, et al. Human rabies prevention—United States, 2008:     106. Mustafa MM, et al. Subacute measles encephalitis in the young
                        recommendations of the Advisory Committee on Immunization   immunocompromised host: report of two cases diagnosed by
                        Practices. MMWR Recomm Rep. 2008;57(RR-3):1-28.         polymerase chain reaction and treated with ribavirin and review
                      87. Centers for Disease Control and Prevention (CDC). Human   of the literature. Clin Infect Dis. 1993;16(5):654-660.
                        rabies—Wisconsin, 2010.  MMWR Morb Mortal Wkly Rep.     107. Chua KB, et al. Nipah virus: a recently emergent deadly para-
                        2011;60:1164-1166.                                      myxovirus. Science. 2000;288(5470):1432-1435.
                      88. Sugaya N. Influenza-associated encephalopathy in Japan: patho-    108. Goh KJ, et al. Clinical features of Nipah virus encephalitis among
                        genesis and treatment. Pediatr Int. 2000;42(2):215-218.  pig farmers in Malaysia. N Engl J Med. 2000;342(17):1229-1235.
                      89. Wada T, et al. Differences in clinical manifestations of     109. Daniels P, Ksiazek T, Eaton BT. Laboratory diagnosis of Nipah
                          influenza-associated encephalopathy by age. Microbiol Immunol.   and Hendra virus infections. Microbes Infect. 2001;3(4):289-295.
                        2009;53(2):83-88.                                    110. Chong HT, et al. Treatment of acute Nipah encephalitis with
                      90. Wang IJ, et al. The correlation between neurological evaluations   ribavirin. Ann Neurol. 2001;49(6):810-813.
                        and neurological outcome in acute encephalitis: a hospital-    111. Lo MK, Rota PA. The emergence of Nipah virus, a highly patho-
                        based study. Eur J Paediatr Neurol. 2007;11(2):63-69.   genic paramyxovirus. J Clin Virol. 2008;43(4):396-400.
                      91. Wang GF, Li W, Li K. Acute encephalopathy and encepha-    112. Baylor P, et al. Transverse myelitis in 2 patients with Bartonella
                        litis caused by influenza virus infection.  Curr Opin Neurol.   henselae infection (cat scratch disease).  Clin Infect Dis.
                        2010;23(3):305-311.                                     2007;45(4):e42-e45.
                      92. Mizuguchi M, et al. Acute necrotising encephalopathy of child-    113. Watson GW, et al. Listeria cerebritis: relapse of infection in renal
                        hood: a new syndrome presenting with multifocal, symmetric   transplant patients. Arch Intern Med. 1978;138(1):83-87.
                        brain lesions. J Neurol Neurosurg Psychiatry. 1995;58(5):555-561.    114. Cunha BA, Fatehpuria R, Eisenstein LE. Listeria monocytogenes
                      93. Toovey S. Influenza-associated central nervous system dysfunc-  encephalitis mimicking Herpes Simplex virus  encephalitis: the
                        tion: a literature review. Travel Med Infect Dis. 2008;6(3):114-124.  differential diagnostic importance of cerebrospinal fluid lactic
                      94. Hviid A, Rubin S, Muhlemann K. Mumps.  Lancet.        acid levels. Heart Lung. 2007;36(3):226-231.
                        2008;371(9616):932-944.                              115. Armstrong  RW, Fung PC. Brainstem encephalitis (rhomben-
                      95. Poggio GP, et al. Nested PCR for rapid detection of mumps virus   cephalitis) due to Listeria monocytogenes: case report and
                        in cerebrospinal fluid from patients with neurological diseases.    review. Clin Infect Dis. 1993;16(5):689-702.
                        J Clin Microbiol. 2000;38(1):274-278.                116. Koskiniemi M. CNS manifestations associated with Mycoplasma
                      96. Anderson LJ, Seward JF. Mumps epidemiology and immu-  pneumoniae infections: summary of cases at the University
                        nity: the anatomy of a modern epidemic. Pediatr Infect Dis J.   of Helsinki and review.  Clin Infect Dis. 1993;17(suppl 1):
                        2008;27(suppl 10):S75-S79.                              S52-S57.










            Section05-O-ref.indd   3                                                                                   1/20/2015   4:51:23 PM
   1083   1084   1085   1086   1087   1088   1089   1090   1091   1092   1093